We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
-7.91%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$118M
AUM Growth
-$15.7M
Cap. Flow
+$577K
Cap. Flow %
0.49%
Top 10 Hldgs %
75.47%
Holding
54
New
–
Increased
13
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
AXGN icon
Axogen
AXGN
+$921K
2
PRTA icon
Prothena Corp
PRTA
+$800K
3
BLUE
bluebird bio
BLUE
+$723K
4
TVTX icon
Travere Therapeutics
TVTX
+$593K
5
TXG icon
10x Genomics
TXG
+$468K

Top Sells

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$1.05M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$984K
3
UTHR icon
United Therapeutics
UTHR
+$921K
4
BMY icon
Bristol-Myers Squibb
BMY
+$753K
5
NBIX icon
Neurocrine Biosciences
NBIX
+$737K

Sector Composition

Rank Sector Weight
1 Healthcare 94.79%
2 Energy 5.2%
3 Consumer Staples 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
1
Bristol-Myers Squibb
BMY
$124B
$41.6M 35.32%
716,297
-12,288
-2% -$753K
BDSX icon
2
Biodesix
BDSX
$209M
$8.74M 7.43%
267,414
+15,432
+6% +$428K
NBIX icon
3
Neurocrine Biosciences
NBIX
$17.2B
$8.69M 7.38%
77,240
-7,000
-8% -$737K
PRTA icon
4
Prothena Corp
PRTA
$453M
$8.18M 6.95%
169,574
+13,463
+9% +$800K
ACAD icon
5
Acadia Pharmaceuticals
ACAD
$4.38B
$5.01M 4.26%
240,400
-9,000
-4% -$244K
QDEL icon
6
QuidelOrtho
QDEL
$1.19B
$4.76M 4.05%
65,203
– –
OVV icon
7
Ovintiv
OVV
$16.2B
$4.01M 3.4%
84,200
– –
IMGN
8
DELISTED
Immunogen Inc
IMGN
$3.02M 2.56%
190,000
– –
UTHR icon
9
United Therapeutics
UTHR
$22.7B
$2.48M 2.11%
11,000
-4,000
-27% -$921K
ELUT icon
10
Elutia
ELUT
$42M
$2.37M 2.01%
1,655,184
– –
HROW icon
11
Harrow
HROW
$1.74B
$2.16M 1.83%
150,000
– –
PHR icon
12
Phreesia
PHR
$662M
$1.54M 1.31%
82,700
– –
ALKS icon
13
Alkermes
ALKS
$8.79B
$1.4M 1.19%
50,000
– –
BLUE
14
DELISTED
bluebird bio
BLUE
$1.38M 1.18%
22,760
+10,300
+83% +$723K
CORT icon
15
Corcept Therapeutics
CORT
$9.72B
$1.36M 1.16%
50,000
– –
MASI
16
DELISTED
Masimo
MASI
$1.34M 1.14%
15,280
– –
FHTX icon
17
Foghorn Therapeutics
FHTX
$305M
$1.32M 1.13%
264,843
– –
AXDX
18
DELISTED
Accelerate Diagnostics
AXDX
$1.3M 1.1%
225,239
– –
INBX
19
DELISTED
Inhibrx, Inc. Common Stock
INBX
$1.29M 1.1%
70,448
– –
ETRN
20
DELISTED
Equitrans Midstream Corporation Common Stock
ETRN
$1.25M 1.06%
133,050
– –
ATEC icon
21
Alphatec Holdings
ATEC
$1.31B
$1.04M 0.88%
80,000
– –
VTYX
22
DELISTED
Ventyx Biosciences
VTYX
$917K 0.78%
26,400
– –
PXD
23
DELISTED
Pioneer Natural Resource Co.
PXD
$872K 0.74%
3,800
– –
TXG icon
24
10x Genomics
TXG
$5.55B
$866K 0.74%
21,000
+9,000
+75% +$468K
AXGN icon
25
Axogen
AXGN
$2.12B
$865K 0.73%
173,000
+133,000
+333% +$921K
1
2 3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q3 2023 Portfolio in Review

As of Q3 2023, Birchview Capital held 54 positions worth $118M, down 12% from $133M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Birchview Capital's Q3 2023 filing shows 13 increased, 4 reduced and 3 closed positions. The largest sale was Soleno Therapeutics, an estimated $1.05M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital added most to Axogen in Q3 2023, an estimated $921K increase.
  • Birchview Capital's biggest Q3 2023 reduction was United Therapeutics, cutting an estimated $921K.
  • Birchview Capital fully exited Soleno Therapeutics in Q3 2023, selling an estimated $1.05M.
  • Birchview Capital's ten largest holdings make up 75% of its $118M portfolio in Q3 2023.
  • Birchview Capital opened 0 new positions and closed 3 in Q3 2023.
  • Birchview Capital's portfolio value fell 12% quarter-over-quarter to $118M.

Based on Birchview Capital's 13F filing for Q3 2023, filed 14 Nov 2023.